May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Bevacizumab for Choroidal Neovascularisation in Pathological Myopia
Author Affiliations & Notes
  • S. Schmidt
    Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
  • A. E. Hoeh
    Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
  • K. B. Schaal
    Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
  • F. Schutt
    Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
  • S. Dithmar
    Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
  • Footnotes
    Commercial Relationships  S. Schmidt, None; A.E. Hoeh, None; K.B. Schaal, None; F. Schutt, None; S. Dithmar, None.
  • Footnotes
    Support  Gertrud Kusen Foundation (Di2008)
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3455. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Schmidt, A. E. Hoeh, K. B. Schaal, F. Schutt, S. Dithmar; Intravitreal Bevacizumab for Choroidal Neovascularisation in Pathological Myopia. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3455.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the safety and efficacy of intravitreal bevacizumab as treatment for choroidal neovascularisation due to pathological myopia (mCNV).

Methods: : Consecutive series of 23 patients with primary or recurrent mCNV treated with intravitreal bevacizumab 1.25mg after being thoroughly informed about the off-label character of the treatment. 17 patients received bevacizumab treatment only, 6 patients additional photodynamic therapy at the time of first injection. Best corrected visual acuity (EDTRS), ophthalmic examination and OCT were performed at baseline and at 6-week intervals. Fluorescein-angiography was performed depending on the clinical and OCT-findings. Reinjections were given every 6 weeks if intra- or subretinal fluid persisted.

Results: : Pre-injection mean visual acuity was 0.29 (0.52 logMAR±0.21). During a follow up of 17±14 weeks 1.39±0.8 injections were given. One eye received 4 injections, 2 eyes 3 injections, 2 eyes 2 injections and 18 eyes only one injection. Complete resorption of sub- or intraretinal fluid and inactivation of mCNV shown by angiography were achieved in all patients. Visual acuitiy (VA) improved by 2.8±5.3 lines on average. 9 eyes showed a significant improvement of at least 3 lines, 14 eyes remaind stable and none lost more than one line. No intraocular or systemic side effects were observed.

Conclusions: : In this so far largest series of patients with mCNV treated with intravitreal bevacizumab, the treatment seems to be effective and safe.

Keywords: myopia • choroid: neovascularization • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×